Interleukin-18 (IL-18) is a highly regulated inflammatory cytokine that is elevated in synovial tissues and synovial fluids of patients with rheumatoid arthritis (RA) compared with patients with osteoarthritis (OA) and patients with other arthropathies. Within the RA joint, IL-18 can contribute to the inflammatory process by inducing leukocyte extravasation through upregulation of endothelial cell adhesion molecules, the release of chemokines from RA synovial fibroblasts, and directly as a monocytes, lymphocyte, and neutrophil chemoattractant. IL-18 can also help maintain and develop the inflammatory pannus by inducing endothelial cell migration and angiogenesis. IL-18 does this directly by binding and activating endothelial cells and indirectly by inducing RA synovial fibroblasts to produce angiogenic chemokines and vascular endothelial growth factor. IL-18 is present in RA synovial fluid in high levels, where it functions as an angiogenic mediator and leukocyte chemoattractant. IL-18 mediates all these inflammatory processes by binding to its receptor, IL-18 receptor, and initiating the activation of different signaling cascades leading to changes in target cells gene expression and behavior. IL-18 has been identified as a potential therapeutic target in the treatment of RA.
AminMA, RabquerBJ, MansfieldPJ, RuthJH, MarotteH, HaasCS, ReamerEN, KochAE. 2010. Interleukin 18 induces angiogenesis in vitro and in vivo via Src and Jnk kinases. Ann Rheum Dis, 69,12:2204–2212.
3.
ArielA, NovickD, RubinsteinM, DinarelloCA, LiderO, HershkovizR. 2002. IL-12 and IL-18 induce MAP kinase-dependent adhesion of T cells to extracellular matrix components. J Leukoc Biol, 72,1:192–198.
4.
BresnihanB, Roux-LombardP, MurphyE, KaneD, FitzGeraldO, DayerJM. 2002. Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. Ann Rheum Dis, 61,8:726–729.
5.
CanettiCA, LeungBP, CulshawS, McInnesIB, CunhaFQ, LiewFY. 2003. IL-18 enhances collagen-induced arthritis by recruiting neutrophils via TNF-alpha and leukotriene B4. J Immunol, 171,2:1009–1015.
6.
CaoR, FarneboJ, KurimotoM, CaoY. 1999. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB Journal, 13,15:2195–2202.
7.
ChandrasekarB, ValenteAJ, FreemanGL, MahimainathanL, MummidiS. 2006. Interleukin-18 induces human cardiac endothelial cell death via a novel signaling pathway involving NF-kappaB-dependent PTEN activation. Biochem Biophys Res Commun, 339,3:956–963.
8.
ChoML, JungYO, MoonYM, MinSY, YoonCH, LeeSH, ParkSH, ChoCS, JueDM, KimHY. 2006. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett, 103,2:159–166.
9.
DaiSM, ShanZZ, XuH, NishiokaK. 2007. Cellular targets of interleukin-18 in rheumatoid arthritis. Ann Rheum Dis, 66,11:1411–1418.
10.
GracieJA, ForseyRJ, ChanWL, GilmourA, LeungBP, GreerMR, KennedyK, CarterR, WeiXQ, XuDothers.1999. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest, 104,10:1393–1401.
HaasCS, AminMA, AllenBB, RuthJH, HainesGK3rd, WoodsJM, KochAE. 2006. Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum, 54,8:2402–2414.
13.
JoostenLA, SmeetsRL, KoendersMI, van den BersselaarLA, HelsenMM, Oppers-WalgreenB, LubbertsE, IwakuraY, van de LooFA, van den BergWB. 2004. Interleukin-18 promotes joint inflammation and induces interleukin-1-driven cartilage destruction. Am J Pathol, 165,3:959–967.
14.
JoostenLA, vanDLFA, LubbertsE, HelsenMM, NeteaMG, vanDMJW, DinarelloCA, vanDBWB. 2000. An IFN-gamma-independent proinflammatory role of IL-18 in murine Streptococcal cell wall arthritis. J Immunol, 165,11:6553–6558.
15.
KawashimaM, MiossecP. 2003. Heterogeneity of response of rheumatoid synovium cell subsets to interleukin-18 in relation to differential interleukin-18 receptor expression. Arthritis Rheum, 48,3:631–637.
16.
KimSH, EisensteinM, ReznikovL, FantuzziG, NovickD, RubinsteinM, DinarelloCA. 2000. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A, 97,3:1190–1195.
17.
Komai-KomaM, GracieJA, WeiXQ, XuD, ThomsonN, McInnesIB, LiewFY. 2003. Chemoattraction of human T cells by IL-18. J Immunol, 170,2:1084–1090.
18.
LengJ, YaoH, ShenJ, WangK, ZhuoG, WangZ. 2008. Co-expression of IL-18 binding protein and IL-4 regulates Th1/Th2 cytokine response in murine collagen-induced arthritis. Acta Biochim Biophys Sin (Shanghai), 40,2:116–124.
19.
LeungBP, CulshawS, GracieJA, HunterD, CanettiCA, CampbellC, CunhaF, LiewFY, McInnesIB. 2001. A role for IL-18 in neutrophil activation. J Immunol, 167,5:2879–2886.
20.
MarotteH, AhmedS, RuthJH, KochAE. 2010. Blocking ERK-1/2 reduces tumor necrosis factor alpha-induced interleukin-18 bioactivity in rheumatoid arthritis synovial fibroblasts by induction of interleukin-18 binding protein A. Arthritis Rheum, 62,3:722–731.
21.
MehtaVB, HartJ, WewersMD. 2001. ATP-stimulated release of interleukin (IL)-1beta and IL-18 requires priming by lipopolysaccharide and is independent of caspase-1 cleavage. J Biol Chem, 276,6:3820–3826.
22.
MollerB, KesslerU, RehartS, KalinaU, OttmannOG, KaltwasserJP, HoelzerD, Kukoc-ZivojnovN. 2002. Expression of interleukin-18 receptor in fibroblast-like synoviocytes. Arthritis Res, 4:139–144.
23.
MollerB, PaulukatJ, NoldM, BehrensM, Kukoc-ZivojnovN, KaltwasserJP, PfeilschifterJ, MuhlH. 2003. Interferon-gamma induces expression of interleukin-18 binding protein in fibroblast-like synoviocytes. Rheumatology (Oxford), 42,3:442–445.
24.
MorelJC, ParkCC, KumarP, KochAE. 2001a. Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NFkappaB activation. Lab Invest, 81,10:1371–1383.
25.
MorelJC, ParkCC, WoodsJM, KochAE. 2001b. A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem, 276,40:37069–37075.
NakanishiK, YoshimotoT, TsutsuiH, OkamuraH. 2001. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol, 19:423–474.
28.
NovickD, KimSH, FantuzziG, ReznikovLL, DinarelloCA, RubinsteinM. 1999. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity, 10,1:127–136.
29.
ParkCC, MorelJC, AminMA, ConnorsMA, HarlowLA, KochAE. 2001. Evidence of il-18 as a novel angiogenic mediator. J Immunol, 167,3:1644–1653.
30.
Petrovic-RackovL, PejnovicN. 2006. Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis. Clin Rheumatol, 25,4:448–452.
31.
Plater-ZyberkC, JoostenLA, HelsenMM, Sattonner-RocheP, SiegfriedC, AlouaniS, van de LooFA, GraberP, AloniS, CirilloRothers.2001. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest, 108,12:1825–1832.
32.
RuthJH, ParkCC, AminMA, LeschC, MarotteH, ShahraraS, KochAE. 2010. Interleukin-18 as an in vivo mediator of monocyte recruitment in rodent models of rheumatoid arthritis. Arthritis Res Ther, 12,3:R118.
33.
RuthJH, ShahraraS, ParkCC, MorelJC, KumarP, QinS, KochAE. 2003. Role of macrophage inflammatory protein-3alpha and its ligand CCR6 in rheumatoid arthritis. Lab Invest, 83,4:579–588.
34.
ShaoXT, FengL, GuLJ, WuLJ, FengTT, YangYM, WuNP, YaoHP. 2009. Expression of interleukin-18, IL-18BP, and IL-18R in serum, synovial fluid, and synovial tissue in patients with rheumatoid arthritis. Clin Exp Med, 9,3:215–221.
SmeetsRL, van de LooFA, ArntzOJ, BenninkMB, JoostenLA, van den BergWB. 2003. Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther, 10,12:1004–1011.
37.
SugawaraS, UeharaA, NochiT, YamaguchiT, UedaH, SugiyamaA, HanzawaK, KumagaiK, OkamuraH, TakadaH. 2001. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J Immunol, 167,11:6568–6575.
38.
TakPP, BacchiM, BertolinoM. 2006. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinet, 31,2:109–116.
39.
VeenbergenS, SmeetsRL, BenninkMB, ArntzOJ, JoostenLA, van den BergWB, van de LooFA. 2010. The natural soluble form of IL-18 receptor beta exacerbates collagen-induced arthritis via modulation of T-cell immune responses. Ann Rheum Dis, 69,1:276–283.
WannamakerW, DaviesR, NamchukM, PollardJ, FordP, KuG, DeckerC, CharifsonP, WeberP, GermannUAothers.2007. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther, 321,2:509–516.
42.
WeiXQ, LeungBP, ArthurHM, McInnesIB, LiewFY. 2001. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol, 166,1:517–521.
43.
YamamuraM, KawashimaM, TaniaiM, YamauchiH, TanimotoT, KurimotoM, MoritaY, OhmotoY, MakinoH. 2001. Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum, 44,2:275–285.
44.
ZeiselMB, NeffLA, RandleJ, KleinJP, SibiliaJ, WachsmannD. 2004. Impaired release of IL-18 from fibroblast-like synoviocytes activated with protein I/II, a pathogen-associated molecular pattern from oral streptococci, results from defective translation of IL-18 mRNA in pro-IL-18. Cell Microbiol, 6,6:593–598.
